51
|
Jaspersen D. Fall 2118. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1234230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
52
|
Jaspersen D. Fall 2073. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
53
|
Jaspersen D, Wzatek J, Haas J. Fall 2068. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
54
|
Jaspersen D. Fall 2065. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
55
|
Jaspersen D. Fall 2124. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
56
|
Jaspersen D. Fall 2100. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
57
|
Jaspersen D, Kronsbein H. Fall 2109. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
58
|
Jaspersen D, Körner T. Fall 2056. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
59
|
Jaspersen D, Haas J. Fall 2140. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
60
|
Jaspersen D. Fall 2017. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
61
|
Jaspersen D, Kronsbein H. Fall 2115. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1234225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
62
|
Jaspersen D. Fall 2069. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
63
|
Jaspersen D. Fall 2023. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
64
|
Jaspersen D, Kronsbein H. Fall 2108. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
65
|
Jaspersen D. Fall 2147. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0029-1235056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
66
|
Jaspersen D, Nocon M, Labenz J, Leodolter A, Richter K, Stolte M, Vieth M, Lind T, Willich SN, Malfertheiner P. Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care--a 5-year follow-up. Aliment Pharmacol Ther 2009; 29:1172-8. [PMID: 19243356 DOI: 10.1111/j.1365-2036.2009.03981.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Gastro-oesophageal reflux disease (GERD) can be associated with laryngo-respiratory symptoms (LRS) such as chronic cough, asthma or laryngeal symptoms. AIM To analyse the long-term clinical course of LRS in a large population with GERD and LRS. METHODS ProGERD is a prospective multicentre cohort study of 6215 adult out-patients with GERD. At baseline, the prevalence of LRS was assessed. Initial standardized treatment was esomeprazole for up to 8 weeks. After 5 years of follow-up, patients were interviewed for LRS and a multivariate analysis was performed with resolved vs. persistent symptoms for chronic cough, asthma and laryngeal symptoms. RESULTS In all, 2886 patients (46.4%) were available for analysis at baseline and at 5 years. The prevalence of chronic cough and laryngeal disorders had decreased while the prevalence of asthma had increased. Resolution of LRS was independent of clinical reflux characteristics or PPI medication. CONCLUSIONS In a large population with GERD, only few patients reported persistent LRS over 5 years. Resolution of LRS was independent of the stage of GERD and PPI treatment. Accordingly, data on the direction of causality between GERD and LRS are lacking and the strength of the association between the two must remain controversial.
Collapse
|
67
|
Nocon M, Labenz J, Jaspersen D, Leodolter A, Richter K, Vieth M, Lind T, Malfertheiner P, Willich SN. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study. Aliment Pharmacol Ther 2009; 29:662-8. [PMID: 19183146 DOI: 10.1111/j.1365-2036.2008.03921.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Gastro-oesophageal reflux disease (GERD) is a common disorder associated with substantial reductions in health-related quality of life (HRQL). AIM To describe patterns of change in HRQL during 5 years of follow-up in a large population of GERD patients. METHODS In 2000, a total of 6215 GERD patients were enrolled in the Progression of GERD (ProGERD) study. During follow-up, patients received any medication considered necessary. HRQL was assessed yearly with the Short-Form 36 and the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaires. Associations between patient characteristics and changes in HRQL were analysed using multiple logistic regression models. RESULTS After 5 years, data on HRQL were available for 4597 (74%) patients. Both generic and disease-specific HRQL improved after baseline and remained well above baseline levels in the following years. A clinically relevant decrease in QOLRAD scores was reported by 3-5% of patients. According to our multivariate analysis, a decrease in HRQL was associated with a higher reflux symptom load and the presence of night-time heartburn. CONCLUSIONS Only a small minority of the ProGERD population reported a clinically relevant decrease in HRQL, which was associated most strongly with nocturnal heartburn.
Collapse
|
68
|
Monkemuller K, Neumann H, Nocon M, Vieth M, Labenz J, Willich SN, Stolte M, Hocker M, Jaspersen D, Lind T, Malfertheiner P. Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: a matched case-control study. Aliment Pharmacol Ther 2008; 28:491-6. [PMID: 18557987 DOI: 10.1111/j.1365-2036.2008.03769.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Gastrin and pepsinogens reflect the functional state of the gastric mucosa. AIM To evaluate whether serum gastrin and pepsinogens correlate with the different grades of severity of gastro-oesophageal reflux disease (GERD). METHODS In all, 388 patients with heartburn not taking any form of acid suppressive therapy were matched-controlled for age and gender and sub-classified into four groups: group 1 non-erosive reflux disease (NERD); group 2, erosive reflux disease (ERD) Los Angeles (LA) A and B, group 3, ERD LA C and D; group 4 Barrett's oesophagus (BO). Fasting serum was analysed for gastrin 17, pepsinogen I, pepsinogen II und Helicobacter pylori using specific EIA tests (GastroPanel; Biohit, Plc). STATISTICS Kruskal-Wallis test and analysis of variance. RESULTS There was a significant difference among the four groups with respect for pepsinogen I, but not for pepsinogen II, the pepsinogen I pepsinogen II ratio, H. pylori serology and gastrin levels. Pepsinogen I was the lowest in NERD and the highest in BO (median 91.6, mean +/- standard deviation 106.2 +/- 51.6 vs. median 114.7, mean +/- standard deviation 130.4 +/- 70.6; P = 0.046). Pepsinogen I levels were higher in H. pylori positive subjects. After adjusting for H. pylori status, the differences in pepsinogen I across patient groups were no longer statistically significant (P = 0.298). CONCLUSIONS Serum gastrin and pepsinogen I and II do not correlate with the different grades of severity of GERD. The non-invasive GastroPanel is not useful for the differentiation of the various forms of GERD.
Collapse
|
69
|
Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study. Aliment Pharmacol Ther 2007; 25:715-22. [PMID: 17311605 DOI: 10.1111/j.1365-2036.2007.03249.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Gastro-oesophageal reflux disease (GERD) is a common condition frequently requiring long-term pharmacological treatment. AIM To describe the long-term pattern of GERD medication use in GERD patients receiving routine care. METHODS Patients were recruited as part of the ongoing ProGERD study, a 10-year-cohort study including 6215 patients at baseline. GERD medication and symptoms were assessed with patient questionnaires. During follow-up, medical treatment was prescribed by participating primary care physicians. Associations between patient characteristics and medication were analysed by logistic regression. RESULTS The percentage of patients who reported using any GERD medication remained constant from year 1 to year 4 (74%, 74%, 73% and 71%). Of patients who reported using GERD medication, the majority were taking proton pump inhibitors (PPI) (79%, 84%, 85%, and 87%). Continuous PPI intake was the predominant prescription pattern (53%, 49%, 56% and 56%), followed by on-demand treatment (26%, 35%, 29% and 29%). Continuous PPI intake was strongly associated with the presence of erosive GERD. CONCLUSION Three-quarters of the GERD population in our study reported long-term treatment with a PPI. Continuous PPI intake was the predominant treatment pattern, and the proportion of patients taking a PPI on a continuous basis remained constant over time.
Collapse
|
70
|
Jaspersen D. Extraesophageal manifestations in gastroesophageal reflux disease. MINERVA GASTROENTERO 2006; 52:269-74. [PMID: 16971871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Gastroesophageal reflux disease (GERD) is a common condition that affects about 20-30% of the adult population, presenting with a broad spectrum of symptoms and varying degrees of severity and frequency. Other manifestations are being increasingly recognized: the so-called ''extraesophageal'' manifestations, such as laryngitis, hoarseness, chronic cough, asthma, or non-cardiac chest pain. Epidemiological studies consistently demonstrate significant associations between pulmonary manifestations and GERD. Up to 50% of patients with an endoscopically proven esophagitis suffer from symptoms other than heartburn or acid regurgitation. However, the published estimates of extraesophageal disorders in patients with GERD vary widely, which may be a result of referral bias. The most effective initial approach in suspected reflux-related extraesophageal symptoms is empiric proton pump inhibitor (PPI) therapy. However, studies demonstrated that the advantage of long-term PPI treatment over placebo could have been overestimated.
Collapse
|
71
|
Jaspersen D, Labenz J, Willich SN, Kulig M, Nocon M, Leodolter A, Lind T, Meyer-Sabellek W, Vieth M, Stolte M, Malfertheiner P. Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis 2006; 38:233-8. [PMID: 16413233 DOI: 10.1016/j.dld.2005.10.026] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2005] [Revised: 10/12/2005] [Accepted: 10/27/2005] [Indexed: 12/11/2022]
Abstract
BACKGROUND Gastro-oesophageal reflux disease can be associated with extra-oesophageal reflux disease such as chronic cough or laryngeal symptoms. The aim of this study was to analyse the clinical course of extra-oesophageal reflux disease in a large population with gastro-oesophageal reflux disease and extra-oesophageal reflux disease under routine clinical care. METHODS ProGERD is a prospective multicentre cohort study of 6215 outpatients with gastro-oesophageal reflux disease. At baseline all patients underwent endoscopies and were interviewed for extra-oesophageal reflux disease. Initial standardised treatment was esomeprazole for up to 8 weeks. After 2 years of follow-up, reflux symptoms and the prevalence of extra-oesophageal reflux disease were assessed. A multivariate analysis was performed with resolved versus persistent symptoms for chronic cough and laryngeal symptoms as dependent predictors. Independent variables were gender, age, body mass index (BMI), alcohol consumption, cigarette smoking, gastro-oesophageal reflux disease classification, history of gastro-oesophageal reflux disease in the family, duration of gastro-oesophageal reflux disease and proton pump inhibitors medication. RESULTS Four thousand four hundred and four patients (71%) were available for analysis at 2 years, including 570 and 454 patients who had chronic cough and laryngeal disorders at baseline, respectively. In 63% and 74% of the patients, chronic cough and laryngeal disorders had resolved. Patients with persistent respiratory symptoms in year 2 had significantly more reflux symptoms. Further clinically relevant associations were smoking and non-steroidal anti-inflammatory drugs use. According to the multivariate analysis, classification of gastro-oesophageal reflux disease, proton pump inhibitors medication or duration of gastro-oesophageal reflux disease were not associated with the resolution of cough or laryngeal symptoms. CONCLUSION In most patients with gastro-oesophageal reflux disease and extra-oesophageal reflux disease, respiratory symptoms resolve during long-term routine care. A high reflux symptom load was associated with the persistence of respiratory disorders.
Collapse
|
72
|
Willich SN, Nocon M, Kulig M, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 2006; 23:371-6. [PMID: 16422996 DOI: 10.1111/j.1365-2036.2006.02763.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Gastro-oesophageal reflux disease (GERD) is a common and frequently chronic condition that causes considerable costs. AIM To estimate the economic burden caused by patients with erosive and non-erosive reflux disease, and Barrett's oesophagus. METHODS The Progression of Gastro-oesophageal Reflux Disease study includes a total of 6,215 patients. At baseline, patients were categorized as non-erosive reflux disease, erosive reflux disease, or Barrett's oesophagus according to endoscopic findings alone or as confirmed by histology. Direct and indirect disease-related costs were calculated based on 5,273 patients with complete information in the second year of the study. RESULTS A total of 73% of the Progression of Gastro-oesophageal Reflux Disease patients had taken GERD medication, 61% had visited a doctor, and 2% had been hospitalized because of GERD during the previous 12 months. Of all employed persons, 6% reported days off work because of GERD. This health resource utilization caused direct costs of 342+/-864 (mean+/-s.d.) and indirect costs of 40+/-473 per patient and year. Total costs for patients with Barrett's oesophagus or erosive reflux disease were higher than those for patients with non-erosive reflux disease. CONCLUSION Patients with GERD frequently need long-term medication and doctor care. The disorder is associated with a considerable health economic burden to society.
Collapse
|
73
|
Vieth M, Kulig M, Leodolter A, Nauclér E, Jaspersen D, Labenz J, Meyer-Sabellek W, Lind T, Willich S, Malfertheiner P, Stolte M. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther 2006; 23:313-9. [PMID: 16393312 DOI: 10.1111/j.1365-2036.2006.02752.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND Proton pump inhibitor therapy has been reported to reduce proliferative changes of the oesophagus significantly in gastro-oesophageal reflux disease (GERD). AIM To assess the histological effects of esomeprazole treatment on the oesophagus. METHODS Data were derived from a subgroup of patients participating in the proGERD study, who had either erosive reflux disease (n = 720) or non-erosive reflux disease (n = 35) and who had biopsy data from two sites [(i) 2 cm above the z-line and (ii) at the z-line], obtained at baseline and following treatment with esomeprazole. Proliferative changes of the squamous epithelium were assessed histologically by measuring thickness of the basal cell layer and elongation of the papillae as a percentage of the whole epithelial thickness. RESULTS In erosive reflux disease patients, the thickness of the basal cell layer and length of the papillae pretreatment were associated with the severity of oesophagitis (P < 0.05), at both biopsy sites. After esomeprazole treatment, baseline thickness and length of papillae were significantly reduced (P < 0.05) at both biopsy sites in non-erosive reflux disease and erosive reflux disease patients (particularly those with Los Angeles grades C and D). CONCLUSION This demonstrates a strong correlation between severity of GERD and histological parameters. Esomeprazole therapy resulted in clear reversal of proliferative changes observed prior to treatment in the squamous epithelium at both biopsy locations.
Collapse
|
74
|
Bandorski D, Diehl KL, Jaspersen D. [Capsule endoscopy in patients with cardiac pacemakers: current situation in Germany]. ZEITSCHRIFT FUR GASTROENTEROLOGIE 2005; 43:715-8. [PMID: 16088768 DOI: 10.1055/s-2005-858469] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND AND AIMS The study evaluated the actually experience of capsule endoscopy (CE) in patients with electrical implants (cardiac pacemaker/defibrillator) in Germany. PATIENTS AND METHODS A standardized questionnaire was sent to all centers in Germany doing capsule endoscopy. The questionnaire covers the number of examined patients, monitoring during CE, check of the electric implants before and after CE, occurrence of arrhythmia, quality of CE-video, complications, location and indication of CE. RESULTS The questionnaire was sent to 154 hospitals and 51 surgeries. 43% of the questionnaires were sent back to our hospital. In 28 centers 45 Patients with a cardiac pacemaker (CP) and 8 patients with a defibrillator (ICD) were examined with CE. There were no relevant complications. In only two cases supraventricular extrasystoles were seen. 93% of patients with a cardiac pacemaker and 67% of the patients with a defibrillator were examined in a hospital. The predominant indication (patients with CP 86%, patients with ICD 67%) was a gastrointestinal bleeding. CONCLUSION There are limited experiences of CE in patients with electric implants in Germany. Domain of CE is the diagnostic of gastrointestinal bleeding. Through the results of the inquiry you can conclude that CE in patients with cardiac pacemakers seems to be acceptable in the clinics.
Collapse
|
75
|
Micklefield G, Jaspersen D, Rasche K, Hildmann H. [Topic complex V: Extra-esophageal manifestations]. ZEITSCHRIFT FUR GASTROENTEROLOGIE 2005; 43:182-4. [PMID: 15700211 DOI: 10.1055/s-2005-857875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|